Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 3/20 | 0.61 |
| ▸ | XDH | P47989 | 1/20 | 0.57 |
| ▸ | BRAF | P15056 | 2/20 | 0.55 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3004037 | 0.85 | NPC1 (0.69) | SRCBRAFTNNI3K | |
| SCHEMBL5840446 | 0.82 | MKNK1 (0.63) | SRCXDHBRAFTNNI3K | |
| SCHEMBL2996504 | 0.82 | XDH (0.57) | SRCXDHBRAFTNNI3K | |
| SCHEMBL3001381 | 0.82 | TNNI3K (0.61) | SRCXDHBRAFTNNI3K | |
| SCHEMBL5827851 | 0.81 | MAPT (0.78) | XDH | |
| SCHEMBL15121705 | 0.81 | BRAF (0.60) | XDHBRAFTNNI3K | |
| SCHEMBL3000771 | 0.80 | MAPT (0.52) | SRC | |
| SCHEMBL4913787 | 0.80 | RAB9A (0.72) | BRAF | |
| SCHEMBL5841027 | 0.80 | BRAF (0.74) | XDHBRAFTNNI3K | |
| SCHEMBL28470488 | 0.77 | SRC (0.54) | SRCBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2173173-B1 | SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES | UNIV PALACKEHO (CZ) | 2013-07-24 | — | — | EP | disclosed |
| US-8222260-B2 | Substituted 6-anilinopurine derivatives as inhibitors of cytokinin oxidase/dehydrogenase and preparations containing these derivatives | Univerzita Palackego V Olomouci (CZ) | 2012-07-17 | — | — | US | disclosed |
| WO-2010118367-A2 | ANTIVIRAL PYRIMIDINES | PROGENICS PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100190806-A1 | SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190806-A1 | SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES | DPYD, XDH, APRT | SRC 4161/4885XDH 2/4885BRAF 2919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.